TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00429234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Starting dose of 800 mg/m\^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
Study: NCT00696020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL/tiotropium bromide fixed dose combination
Description: BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL/tiotropium bromide fixed dose combination
Description: BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL/tiotropium bromide fixed dose combination
Description: BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide
Description: tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat® Inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat® Inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat® Inhaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat® Inhaler
Study: NCT01545830

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 (cholecalciferol)
Description: Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 (cholecalciferol)
Description: Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
Study: NCT03260465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: seleXys PC
Description: Total hip arthroplasty using the seleXys PC cup

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RM
Description: Total hip arthroplasty using the RM cup
Study: NCT00233194

Intervention type: PROCEDURE
Intervention: Observational follow-up study of adenotonsillectomy
Description: Studies of sleep, behavior, cognition, and daytime sleepiness
Study: NCT01232426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodegradable Meniscus Arrow®
Description: Closed reduction of the Mallet fracture and fixation with 1 biodegradable meniscus Arrow®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mallet splint
Description: Conservative treatment of the Mallet fracture with the traditional Mallet splint.
Study: NCT03920904

Intervention type: OTHER
Intervention: Collection of blood samples
Description: Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
Study: NCT02762773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-dissection of inferior rectus sheath
Description: Non-dissection of inferior rectus sheath

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Dissection of inferior and superior aspect of the rectus sheath
Study: NCT02723045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Lichtenstein Hernioplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TEP Hernioplasty
Study: NCT02969408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate
Description: Albuterol sulfate will be administered as per the dose and schedule specified in the arm.
Study: NCT02131857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active interventional program based on Mindfulness training
Description: active interventional program based on Mindfulness training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active interventional program based on Mindfulness training
Description: active interventional program based on Mindfulness training
Study: NCT04154579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeRe We Arts
Description: Art Therapy interventions to promote health, resilience \& well-being will discussed; \& experiences such as key chain making, collaging on journal covers, creating sculpture garden will be utilized. Music therapy interventions such as lyric discussion, singing, instrument playing, \& music-assisted relaxation techniques will be utilized; \& discussion of use of music to elicit positive physical \& emotional responses will be held. Drums Alive (drumming \& movement) will be used to promote physical activity. Art appreciation will include discussion of public art forms. Journaling will include different techniques for journaling, writing poetry, etc. Theater games such as Password, Press Conference, Props Only, \& Draw What You Hear will be utilized. Chair yoga will be introduced as a form of exercise. Education will be provided on the various topics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HeRe We Ed
Description: Educational components and some experiential components will be utilized to educate the participants on health, resilience, well-being, nutrition, healthy eating, weight management, eating disorders, obesity, exercise, physical activity, sleep hygiene and the importance of sleep, mental health, stress management, the importance of improving life satisfaction, holistic approaches, wellness, integrative medicine, complementary and alternative medicine, chronic illness, chronic pain, methods for dealing with chronic versus acute illnesses, changing behaviors and/or maintaining healthy behaviors in order to promote health and stay out of the hospital, and navigating the healthcare system. Specific experiential components will include Chair Yoga and Stress Management Techniques.
Study: NCT01758627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Description: PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
Study: NCT01009840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV busulfan
Description: PK-directed dosing of IV busulfan for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Single IV bortezomib at a dose of 1.3 mg/m\^2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplant (HSCT)
Study: NCT02131857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active interventional program based on Mindfulness training
Description: active interventional program based on Mindfulness training
Study: NCT05035121

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk supplement
Description: Intervention groups provided 200 mL long life milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy milk supplement
Description: Intervention groups provided 200 mL long life soy milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
Study: NCT04022733

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moderate neuromuscular block
Description: maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
Study: NCT03480464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-technology to increase physical activity
Description: The application will send daily reminders to register and notices with information about the health benefit of physical activity, medication, supplementary vitamins and diet after surgery
Study: NCT01050153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin sodium
Description: Dalteparin sodium injection 5000IU subcutaneously daily until fully ambulatory

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium/aspirin
Description: Dalteparin sodium (2500-10,000IU sc daily), aspirin (81-325mg daily) po.
Study: NCT05035121

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: resistance exercise
Description: The participants joined the resistance exercise training program, three times per week (30 min/time)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: The participants joined the resistance exercise training program, three times per week (30 min/time)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: The participants joined the resistance exercise training program, three times per week (30 min/time)
Study: NCT04769791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracuff pressure measurement
Description: intracuff pressure is measured by a pressure manometer
Study: NCT03288883

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photothermal Non-ablative Erbium:YAG-laser
Description: Laser treatment of the vagina for GSM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Microablative CO2-laser
Description: Laser treatment of the vagina for GSM
Study: NCT01642342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02891785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ANtiPain
Description: After the implementation of ANtiPain, patients will receive cancer pain self-management support by trained staff nurses who follow the ANtiPain protocol. ANtiPain is based on 3 key strategies: Provision of information, skill building and nurse coaching. It consists of an in-hospital one-to-one session before discharge and a telephone follow up according to a clinical algorithm based on pain intensity, patient satisfaction with pain management and patient adherence. Patients will be given a booklet with corresponding info. The implementation process will include training of designated staff nurses, coaching activities based on case discussions on the ward, as well as measures to ensure sustainability of the implementation (e.g., training of ward managers and clinical nurse specialists).
Study: NCT02623231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
Study: NCT04769791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracuff pressure measurement
Description: intracuff pressure is measured by a pressure manometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracuff pressure measurement
Description: intracuff pressure is measured by a pressure manometer
Study: NCT01269164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure Composite Facial Transplant
Description: Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
Study: NCT00333216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 30 mg/mL
Description: Posterior juxtascleral administration of suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 60 mg/ML
Description: Posterior juxtascleral administration of suspension

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: Sham posterior juxtascleral administration of suspension
Study: NCT02995434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: The following VR experiences will be used:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ Carpe Lucem: http://store.steampowered.com/app/433700/Carpe_Lucem__Seize_The_Light_VR/

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2D PC
Description: The control group will be exposed to 2D equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). These will be functionally similar to the VR experiences. These will include:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ The Witness: http://store.steampowered.com/app/210970/
Study: NCT02201758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed lignan-enriched complex (FLC)
Description: Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
Study: NCT03812809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-7711
Description: BPI-7711: 180mg, QD, oral
Study: NCT02746510

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Array comparative genomic hybridization
Description: For each of the 150 patients deoxyribose nucleic acid (DNA) exactracted from a jugal mucosae sample will be analysed by the cytogeneticist and a CGH-a will be performed.
Study: NCT03045003

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: RESIL Intervention
Description: Interventions tested in this study are the following: i) educational sessions with oncologists and nurses, ii) direct, electronic feed-back of resilience and needs screening in a monitoring sheet including intervention propositions and iii) consultation provided by a clinical nurse specialist to patients (in intervention B only) Interventions have been developed based on previous studies on the efficacy of screening of patient reported outcomes and direct feed-back to health care professionals and on previous studies on interventions to enhance resilience in nursing or psycho-oncology with proven efficacy. Interventions provided in the monitoring sheet have been validated by experienced Swiss oncology nurses, oncologists and psycho-oncologists.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: RESIL Intervention
Description: Interventions tested in this study are the following: i) educational sessions with oncologists and nurses, ii) direct, electronic feed-back of resilience and needs screening in a monitoring sheet including intervention propositions and iii) consultation provided by a clinical nurse specialist to patients (in intervention B only) Interventions have been developed based on previous studies on the efficacy of screening of patient reported outcomes and direct feed-back to health care professionals and on previous studies on interventions to enhance resilience in nursing or psycho-oncology with proven efficacy. Interventions provided in the monitoring sheet have been validated by experienced Swiss oncology nurses, oncologists and psycho-oncologists.
Study: NCT04788420

Intervention type: DRUG
Intervention: Sorafenib
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
Study: NCT03975192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrical Nerve Field Stimulation
Description: Placement of the PENFS device immediately following the last scheduled opiate dose in the PICU with active stimulation for 120 hours.
Study: NCT00748748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Culturelle
Description: 10\^10 Lactobacillus rhamnosus GG per capsule
Study: NCT04598490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space closure into old extraction space
Description: Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into healed bony socket

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space closure into recent extraction space
Description: Lower first premolar extraction space was closed using elastic power chain and 0.019X0.025 Stainless steel archwire into fresh bony socket
Study: NCT00454779

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: chemotherapy arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: experimental arm

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: chemotherapy arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: experimental arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: experimental arm
Study: NCT02651090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid
Description: Comparison of Sonazoid enhanced ultrasound to non enhanced CT
Study: NCT00332709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg/day for 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg/day for 3 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4 mg every 6 months
Study: NCT02246257

Intervention type: OTHER
Group type: OTHER
Intervention: Simvastatin
Description: LDL \> 2.5 is treated with 40 mg

Intervention type: OTHER
Group type: OTHER
Intervention: Simvastatin
Description: LDL \> 2.5 is treated with 40 mg

Intervention type: OTHER
Group type: OTHER
Intervention: Losartan
Description: BT \> 140/90 mmHg treated with 50 mg OD

Intervention type: OTHER
Group type: OTHER
Intervention: Losartan
Description: BT \> 140/90 mmHg treated with 50 mg OD
Study: NCT01642342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02246257

Intervention type: OTHER
Group type: OTHER
Intervention: Losartan
Description: DM BT \> 130/80 mmHg treated with 50 mg OD

Intervention type: OTHER
Group type: OTHER
Intervention: Losartan
Description: DM BT \> 130/80 mmHg treated with 50 mg OD

Intervention type: OTHER
Group type: OTHER
Intervention: Losartan
Description: Microalbuminuria (urinary albumin creatinin ratio \> 30 mg) treated with 100 mg OD

Intervention type: OTHER
Group type: OTHER
Intervention: Losartan
Description: Microalbuminuria (urinary albumin creatinin ratio \> 30 mg) treated with 100 mg OD
Study: NCT01642342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant albumin fusion protein sEphB4-HSA
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant albumin fusion protein sEphB4-HSA
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant albumin fusion protein sEphB4-HSA
Description: Given IV
Study: NCT02246257

Intervention type: OTHER
Group type: OTHER
Intervention: Metformin
Description: HBA1C \> 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Metformin
Description: HBA1C \> 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Outpatient rheumatology department
Description: (4 times yearly)

Intervention type: OTHER
Group type: OTHER
Intervention: Refered to general practice
Study: NCT01244256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole + Gentamicin + Beclomethasone
Description: Treatment with Clotrimazole + Gentamicin + Beclomethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole + Gentamicin
Description: Treatment with Clotrimazole + Gentamicin
Study: NCT03636763

Intervention type: DRUG
Intervention: data report
Description: the information gliptin exposure will be reported

Intervention type: DRUG
Intervention: data report
Description: the information gliptin exposure will be reported
Study: NCT03995420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy (V-NeST)
Description: V-NeST is a 12-session therapy using psychological intervention principles based on Cognitive Remediation and CBT partly based in Virtual Reality.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: multi-modal treatment consisting of different therapies defined by the treating team. These will include regular contact with a care coordinator and medication management by a psychiatrist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: multi-modal treatment consisting of different therapies defined by the treating team. These will include regular contact with a care coordinator and medication management by a psychiatrist.
Study: NCT04484493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate nasal spray
Description: dose of 2 puff in each nostril (100 µg once daily each nostril).
Study: NCT05908864

Intervention type: DRUG
Intervention: Magnesium sulfate
Description: Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done

Intervention type: DRUG
Intervention: Magnesium sulfate
Description: Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done

Intervention type: DRUG
Intervention: Magnesium sulfate
Description: Blood pressure, respiratory rate, pulse, peak expiratory flow rate (PEFR) measurement using a peak flowmeter, Fischl index and need for hospitalization in patients with acute bronchial asthma were done
Study: NCT00689247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: iv infusion, single dose